First 12 GAPP Projects Selected
News Oct 15, 2014
The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, President and CEO of Genome Canada, have announced the first 12 projects selected for funding under Genome Canada’s Genomic Applications Partnership Program (GAPP). The announcement was made at Wallenstein’s Feed & Supply Ltd., where the Minister toured the company’s animal feed production facilities.
GAPP projects partner academic researchers with “users” of genomics (e.g. industry, provincial governments, non-profits, or other organizations) to translate innovations that are expected to have considerable economic and social impacts within the near term.
Minister Holder highlighted a GAPP project between Elanco Animal Health (a division of Eli Lilly & Co) and Concordia University. Dr. Paul Matzat from Elanco and Dr. Adrian Tsang from Concordia will develop and commercialize new enzyme products for pork and poultry to improve digestion of animal feed. As a result, less animal feed will be wasted, providing for healthier chickens and pigs, reduced costs to farmers and a more competitive pork and poultry industry responsible for thousands of on-farm jobs in Ontario and over 20,000 across Canada.
Further, GAPP projects will support training the next generation of graduate students and post-doctoral fellows, thanks to a new partnership between Genome Canada and Mitacs, which will create research internships for future projects.
The 12 projects announced today involve a total investment of $56 million. The Government of Canada is contributing $15 million through Genome Canada with the balance (about $41 million) invested by co-funding partners including the genomics “user”. These projects comprise the first two rounds of multiple rounds of projects that will be funded under GAPP.
The projects selected for funding hail from Atlantic Canada, Quebec, Ontario, Saskatchewan and British Columbia, and include industries as diverse as aquaculture, cheese-making, horticulture, animal feed, crops, forestry and healthcare.
GAPP is designed to move genomics-based solutions to the marketplace through academic partnerships with industry and other “users” of genomics. It is also intended to stimulate investment from private and public partners to fund projects that address real world challenges and opportunities in the field of genomics.
The new Genome Canada – Mitacs partnership will enable funding and training for graduate students and post-doctoral fellows as they are placed within industry through GAPP projects. It will prepare Canada’s next entrepreneurs through hands-on experience. Interns transfer their skills from theory to real-world application, while the companies gain a competitive advantage by accessing high-quality research expertise.
GAPP was launched in 2013 as a $90 million program, with $30 million of federal funding through Genome Canada and the balance from partner investment (i.e. from industry, government, non-profit and others), leveraged by Genome Canada in collaboration with regional Genome Centres.
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Who Owns the Ocean? One Company Has Registered Half of All Marine Gene PatentsNews
A single corporation has registered nearly half of all existing patents associated with genes from marine organisms, according to a new study. Researchers from the University of British Columbia and the Stockholm Resilience Centre examined the patents associated with marine species and found that BASF, the world’s largest chemical manufacturer, has registered 47 per cent of the 12,998 genetic sequences from 862 marine species.